Avalo Therapeutics, Inc. (AVTX) stock
AVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$6.70−0.43 (-6.03%)
Close on Nov 18, 2026Market cap $359.32MP/E –Yield –
Avalo Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Avalo Therapeutics's revenue for the twelve months ending Dec 31, 2025 was $59.00K, down 86.6% year over year. For fiscal 2025 it was $59.00K, down 86.6% from the year before. The highest annual figure on record is $27.81M in fiscal 2017.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $59.00K | -86.6% |
| FY2024 | Dec 31, 2024 | $441.00K | -77.1% |
| FY2023 | Dec 31, 2023 | $1.92M | -89.3% |
| FY2022 | Dec 31, 2022 | $18.05M | +234.4% |
| FY2021 | Dec 31, 2021 | $5.40M | -19.4% |
| FY2020 | Dec 31, 2020 | $6.70M | -0.8% |
| FY2019 | Dec 31, 2019 | $6.75M | -4.0% |
| FY2018 | Dec 31, 2018 | $7.03M | -74.7% |
| FY2017 | Dec 31, 2017 | $27.81M | +2312.3% |
| FY2016 | Dec 31, 2016 | $1.15M | – |
| FY2015 | Dec 31, 2015 | $0 | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | $59.00K | – |
| Q3 FY2025 | Sep 30, 2025 | $0 | – |
| Q4 FY2024 | Dec 31, 2024 | $192.00K | -66.4% |
| Q3 FY2024 | Sep 30, 2024 | $249.00K | +5.5% |
| Q2 FY2024 | Jun 30, 2024 | $0 | -100.0% |
| Q1 FY2024 | Mar 31, 2024 | $0 | -100.0% |
| Q4 FY2023 | Dec 31, 2023 | $571.00K | -36.3% |
| Q3 FY2023 | Sep 30, 2023 | $236.00K | -98.4% |
| Q2 FY2023 | Jun 30, 2023 | $643.00K | -37.8% |
| Q1 FY2023 | Mar 31, 2023 | $475.00K | -59.5% |
| Q4 FY2022 | Dec 31, 2022 | $896.00K | +309.1% |
| Q3 FY2022 | Sep 30, 2022 | $14.95M | +1007.3% |
| Q2 FY2022 | Jun 30, 2022 | $1.03M | -69.2% |
| Q1 FY2022 | Mar 31, 2022 | $1.17M | +148.0% |
| Q4 FY2021 | Dec 31, 2021 | $219.00K | -85.4% |
| Q3 FY2021 | Sep 30, 2021 | $1.35M | +21.5% |
| Q2 FY2021 | Jun 30, 2021 | $3.36M | +150.7% |
| Q1 FY2021 | Mar 31, 2021 | $473.00K | -82.8% |
| Q4 FY2020 | Dec 31, 2020 | $1.50M | +157.7% |
| Q3 FY2020 | Sep 30, 2020 | $1.11M | -49.5% |
| Q2 FY2020 | Jun 30, 2020 | $1.34M | -3.9% |
| Q1 FY2020 | Mar 31, 2020 | $2.75M | +6.9% |
| Q4 FY2019 | Dec 31, 2019 | $580.81K | -88.3% |
| Q3 FY2019 | Sep 30, 2019 | $2.20M | -46.0% |
| Q2 FY2019 | Jun 30, 2019 | $1.39M | -70.9% |
| Q1 FY2019 | Mar 31, 2019 | $2.58M | -42.5% |
| Q4 FY2018 | Dec 31, 2018 | $4.98M | +160.8% |
| Q3 FY2018 | Sep 30, 2018 | $4.07M | -83.7% |
| Q2 FY2018 | Jun 30, 2018 | $4.79M | +2932.4% |
| Q1 FY2018 | Mar 31, 2018 | $4.48M | +1066.8% |
| Q4 FY2017 | Dec 31, 2017 | $1.91M | +955.8% |
| Q3 FY2017 | Sep 30, 2017 | $25.04M | +7687.8% |
| Q2 FY2017 | Jun 30, 2017 | $157.80K | – |
| Q1 FY2017 | Mar 31, 2017 | $384.21K | – |
| Q4 FY2016 | Dec 31, 2016 | $181.00K | – |
| Q3 FY2016 | Sep 30, 2016 | $321.50K | – |
See a number that looks wrong?